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a b s t r a c t
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneumo-
coccal conjugate vaccines (PCVs). There are few data on the impact of PCVs in lower income settings, par-
ticularly in Asia. In 2013, the Lao People’s Democratic Republic (Lao PDR) introduced 13-valent PCV
(PCV13) as a 3 + 0 schedule (doses at 6, 10 and 14 weeks of age) with limited catch-up vaccination.
We conducted two cross-sectional carriage surveys (pre- and two years post-PCV) to assess the impact
of PCV13 on nasopharyngeal pneumococcal carriage in 5–8 week old infants (n = 1000) and 12–23 month
old children (n = 1010). Pneumococci were detected by quantitative real-time PCR, and molecular
serotyping was performed using DNA microarray. Post PCV13, there was a 23% relative reduction in
PCV13-type carriage in children aged 12–23 months (adjusted prevalence ratio [aPR] 0.77 [0.61–0.96]),
and no significant change in non-PCV13 serotype carriage (aPR 1.11 [0.89–1.38]). In infants too young
to be vaccinated, there was no significant change in carriage of PCV13 serotypes (aPR 0.74 [0.43–1.27])
or non-PCV13 serotypes (aPR 1.29 [0.85–1.96]), although trends were suggestive of indirect effects.
Over 70% of pneumococcal-positive samples contained at least one antimicrobial resistance gene, which
were more common in PCV13 serotypes (p < 0.001). In 12–23 month old children, pneumococcal density
of both PCV13 serotypes and non-PCV13 serotypes was higher in PCV13-vaccinated compared with
undervaccinated children (p = 0.004 and p < 0.001, respectively). This study provides evidence of
PCV13 impact on carriage in a population without prior PCV7 utilisation, and provides important data
from a lower-middle income setting in Asia. The reductions in PCV13 serotype carriage in vaccine-
eligible children are likely to result in reductions in pneumococcal transmission and disease in Lao PDR.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Streptococcus pneumoniae (the pneumococcus) is a leading
cause of childhood mortality worldwide, causing approximately
826,000 deaths each year [1]. Pneumococcal diseases range from
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mild to severe, including pneumonia, meningitis and sepsis. There
are over 95 immunologically distinct capsular types (serotypes).
Current paediatric vaccines target 10 or 13 of the most common
disease causing serotypes.
Nasopharyngeal carriage is considered a prerequisite for disease
[2], and is the primary ecological niche for this human pathogen.
Importantly, carriage underpins the powerful herd effects of pneu-
mococcal conjugate vaccines (PCVs) as vaccinated individuals are
less likely to carry vaccine serotypes, and therefore less likely to
transmit the bacteria to unvaccinated individuals in the commu-
nity [3]. PCVs result in substantial individual (direct) and herd
(indirect) protection against pneumococcal disease [3,4].
PCVs have been introduced nationally into 59 low- and middle-
income countries (LMICs) [5]. However, there are few data on vac-
cine impact in LMIC settings, particularly from Asia. There is also a
paucity of data on the indirect effects for children who are too
young to be vaccinated [4,6,7], but who have high case fatality
rates from pneumococcal disease [8]. Demonstrating vaccine
impact helps justify the cost of PCV introduction and maintenance,
particularly as countries graduate from Gavi eligibility. It is impor-
tant to monitor serotype replacement, whereby non-vaccine sero-
types become more common in carriage and disease following
vaccination, as this may erode vaccine impact over time [9–11].
In many settings, particularly where the pneumococcal disease
burden is high, there is insufficient surveillance to measure vaccine
impact on pneumococcal disease. Although they have limitations,
carriage studies are an efficient and meaningful approach to mea-
sure prevalence of pneumococci and demonstrate the biological
effect of PCV in a population [12]. Carriage studies may be the only
tool available in some settings.
As well as substantially reducing carriage and disease by
vaccine-type pneumococci, PCV introduction can reduce antimi-
crobial resistance (AMR), as vaccine serotypes are more likely to
be resistant compared with non-vaccine serotypes [13]. Although
there is emerging clinical and experimental evidence for the
importance of pneumococcal nasopharyngeal density on the likeli-
hood of disease and transmission [14,15], the effect of PCVs on
pneumococcal density is largely unknown [16,17].
The Lao People’s Democratic Republic (Lao PDR) has a high child
mortality rate of 67/1000 live births and a high burden of child-
hood pneumonia (https://www.gavi.org/country/lao-pdr/
[Accessed 21 May 2018]). The aim of this study was to describe
pneumococcal carriage in children before and after PCV13 intro-
duction in Lao PDR. To do this, we conducted two cross-sectional
community carriage surveys (pre- and two years post-PCV13 intro-
duction) in children aged 12–23 months and 5–8 weeks to assess
direct and indirect effects. We applied sensitive molecular microbi-
ological approaches [18] to describe overall pneumococcal, PCV13
serotype and non-PCV13 serotype carriage rates and density, and
the presence of AMR genes, pre- and post-PCV13 introduction.
2. Methods
2.1. Study site
Lao PDR is a South East Asian lower-middle income country of
approximately seven million inhabitants. Lao PDR is ethnically
diverse, with 49 government-recognised ethnic groups that com-
pose approximately 34% of the population [19]. In 2012, 22.7% of
the population lived below the international poverty line (http://
povertydata.worldbank.org/). With support from Gavi, the Vaccine
Alliance, Lao PDR introduced PCV13 into the national immunisa-
tion program in late 2013, with three doses administered at 6, 10
and 14 weeks of age, with catch-up vaccination to 12 months of
age. National coverage of the third dose of PCV13 was estimated
at 72% for 2014, 77% for 2015, and 78% for 2016 (http://www.
who.int/immunization/monitoring_surveillance/data/lao.pdf). This
study was conducted in Vientiane, the capital and largest city in
Lao PDR, and the nearby rural Bolikhamxay Province.
2.2. Study design and participants
Cross-sectional carriage surveys were conducted from Novem-
ber 2013 – February 2014 (‘‘pre-PCV”), and November 2015 –
February 2016 (‘‘post-PCV”), to assess pneumococcal carriage at
baseline and approximately two years following PCV13
introduction.
Participants were a convenience sample of children living in
urban and rural areas; provinces were selected on the basis of
access to a laboratory to store the swabs on the day of collection,
and status of PCV13 introduction. Urban study participants were
identified and recruited from participating maternal and child
health centres in Vientiane Capital Province during routine clinic
visits. Rural participants were recruited during maternal and child
health visits, and visits to surrounding households, in Bolikhamxay
Province.
Eligibility criteria were age (5–8 week old infants and 12–
23 month old children), an axillary temperature 37 C and having
lived in the area for at least three consecutive months. Children
and infants were excluded from the first survey if they had
received any dose of PCV13, and from the second survey if they
were aged 5–8 weeks and had received PCV13.
Sample size was determined based on the calculation that 281
participants would detect a 50% reduction, with 90% power at a
5% significance level, in PCV13 serotype prevalence assuming a
baseline PCV13 carriage prevalence of 16% [20]. As the true preva-
lence of pneumococcal carriage in Lao PDR was unknown, the sam-
ple size for both age groups was increased to 500 per survey.
The study was conducted according to the protocol approved by
the Lao PDR Ministry of Health National Ethics Committee for
Health Research (061-NECHR), Western Pacific Regional Office
Ethics Review Committee and The Royal Children’s Hospital/Mur-
doch Children’s Research Institute Human Research Ethics Com-
mittee (HREC 33177A/HREC 33177B). Written informed consent
was obtained from the parent or guardian for all participants prior
to any study procedures being conducted. To identify potential
confounders, the study staff completed a questionnaire document-
ing potential risk factors for pneumococcal carriage. PCV13 vacci-
nation status was verified by checking the child’s national
vaccination status card or confirming with health centre records.
2.3. Sample collection and transport
Sample collection, handling and storage were performed
according to World Health Organization guidelines [21]. In brief,
nasopharyngeal samples were collected using paediatric flocked
swabs (Copan Diagnostics) and then placed into 1 ml of skim milk
tryptone glucose glycerol medium (STGG). Samples were trans-
ported to the Lao-Oxford-Mahosot-Hospital-Wellcome Trust-
Research Unit (LOMWRU, Vientiane, Lao PDR) before being vor-
texed, dispensed into aliquots and stored at ultra-low tempera-
tures. Samples were shipped on dry ice to the Murdoch
Children’s Research Institute (Parkville, Australia) for laboratory
testing.
2.4. STGG DNA extraction and lytA qPCR
To screen for the presence, and to determine the colonisation
density, of pneumococci, real-time quantitative PCR targeting the
lytA gene (lytA qPCR) was conducted on the STGG samples. First,
genomic DNA was extracted from 100 ml STGG using the MagNA
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Pure LC machine (Roche) [22]. LytA qPCR [23], with primer and
probe concentrations of 100 nM and 200 nM, respectively, was
performed on all extracted DNA samples. Final reaction volumes
of 25 ml were run on a Stratagene Mx3005 machine using 2 ml tem-
plate DNA and Brilliant III Ultra-Fast qPCR Master Mix (Agilent
Technologies), according to manufacturer’s instructions. Reactions
were performed in duplicate, with the carriage density (in genome
equivalents/ml) calculated using the average cycle threshold (Ct)
value, by reference to a standard curve prepared from reference
isolate genomic DNA [24]. For these calculations, an assumption
was made that each genome has one copy of the lytA gene, and that
the genome size is 2 Mb. Samples that were lytA qPCR positive (Ct
value < 35) or equivocal (Ct value 35–40) were cultured for molec-
ular serotyping by microarray.
2.5. Culture, DNA extraction and microarray
50 ml of STGG were cultured on horse blood agar containing
5 mg/ml of gentamicin (Oxoid). DNA was extracted from the har-
vested growth with the QIAcube HT instrument (Qiagen) and
QIAamp 96 DNA QIAcube HT Kit (Qiagen), using a lysis buffer
(20 mM Tris/HCl, 2 mM EDTA, 1% v/v Triton, 20 mg/ml lysozyme)
and RNase A treatment [18,25]. When only a single a-haemolytic
colony grew, it was subcultured prior to DNA extraction for
microarray, or in some cases serotyped using latex agglutination
[26]. Molecular serotyping by microarray was performed on the
extracted DNA using Senti-SPv1.5 microarrays (BUGS Bioscience),
as described previously [18]. The microarray data was analysed
using a custom web-based software that uses a Bayesian-based
model [27].
2.6. Assessment of pneumococcal carriage
Pneumococcal carriage, and the presence and relative abun-
dance of each pneumococcal serotype, was determined by microar-
ray. PCV13 serotypes included serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F, and 23F. All other serotypes, as well as non-
encapsulated pneumococci [28], were considered non-PCV13 sero-
types. Serotypes 15B and 15C were reported as 15B/C as these ser-
otypes are known to interconvert [29]. Samples that were lytA
qPCR positive (Ct value < 35) but not able to be serotyped (either
culture negative or low DNA yield from culture) were considered
pneumococcal positive, serotype unknown. Samples that were
equivocal by lytA qPCR (Ct value 35–40) and culture-negative were
considered pneumococcal negative. A swab that contained both
PCV13 and non-PCV13 serotype(s) was considered positive for
both PCV13 and non-PCV13 carriage, irrespective of relative abun-
dance or serotype-specific density. To determine serotype-specific
density (genome equivalents/ml), the overall pneumococcal den-
sity (as determined by lytA qPCR) was multiplied by the per cent
relative abundance of each serotype (as determined by
microarray).
The microarray detects 10 AMR genes associated with mobile
genetic elements, encoding tetracycline (tetM, tetK, tetO, tetL), chlo-
ramphenicol (cat), macrolides (mefA), kanamycin (aphA3), strep-
tothricin (sat4), and ermB and ermC genes which encode
resistance to macrolides including erythromycin, as well as resis-
tance to lincosamides and streptogramin B. To examine the pres-
ence of AMR genes, we restricted analysis to samples containing
a single pneumococcal type with no other species identified.
2.7. Statistical analysis
Demographic data were double data entered into EpiData ver-
sion 3.1 databases. The two separate EpiData files were validated,
and corrections made as required using the source document (data
collection form). Further cleaning was conducted in Stata version
15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. College
Station, TX: StataCorp LLC). Laboratory data was imported from
Excel (Microsoft Office) to Stata and merged to the demographic
Stata file.
Statistical analyses was performed using GraphPad Prism ver-
sion 7.04 for Windows, (GraphPad Software) and Stata versions
14.2 and 15.1. The Chi-squared test was used to compare categor-
ical data and the Kruskal-Wallis test for continuous data unless
otherwise noted.
Carriage prevalence of overall pneumococci, PCV13 serotypes,
and non-PCV13 serotypes were determined for the pre- and
post-PCV periods. For each age group, prevalence ratios were cal-
culated by comparing the post-PCV13 period with the pre-PCV13
period. The association between overall carriage and potential con-
founders shown in Table 1 were examined initially via univariable
logistic regression. Those considered associated with overall car-
riage (p < 0.1) were included in multivariable log-binomial regres-
sion models to estimate adjusted prevalence ratios. Month of swab
collection was also included in the adjusted models. If log-binomial
models did not converge, Poisson models with robust 95% confi-
dence intervals (CI) were used [30]. Results are reported as preva-
lence ratios (PR) and adjusted PR (aPR) with 95% CIs. Reductions in
PCV13-serotype carriage were calculated as (1  aPR) * 100%.
Bacterial density data were log10 transformed prior to analysis
to remove skewness, and results reported as log10 genome equiva-
lents/ml (log10 GE/ml). As some density datasets were not nor-
mally distributed, non-parametric methods were used for
analysis. Density data were examined by survey period (pre- and
post-PCV13) for both age groups. To examine potential direct
effects of PCV13 on pneumococcal density, median carriage densi-
ties were calculated for vaccinated (2 or 3 doses of PCV13) and
undervaccinated 12–23 month old children (0 or 1 dose of
PCV13), and compared using quantile regression. To adjust for
potential confounders, a multivariable quantile regression model
included variables identified as associated with overall pneumo-
coccal density by univariable analysis (p < 0.1).
3. Results
Characteristics of the study participants (n = 2010) are shown in
Table 1. Several characteristics, including exposure to cigarette and
cooking fuel smoke, having symptoms of an upper respiratory tract
infection (URTI), and antibiotic use in the proceeding fortnight
were significantly different between the two survey periods. In
the post-PCV13 period, 90% of participants aged 12–23 months
had received PCV13. None of the 5–8 week old infants were
vaccinated.
We determined the pneumococcal carriage status of 2009 chil-
dren; one swab was excluded for technical reasons. Table 2 shows
the carriage prevalence and prevalence ratios for overall pneumo-
coccal carriage pre- and post-PCV13 introduction.
Serotyping results were obtained from 660 of 668
pneumococcal-positive samples. A total of 749 pneumococci were
identified. These included 637 capsular pneumococci belonging to
41 different capsular serotypes, and 112 non-encapsulated pneu-
mococci from five different genetic lineages, with 98% belonging
to the NT2 lineage [28]. Eleven of the PCV13 serotypes were
detected (serotypes 1 and 5 were not identified).
Following PCV13 introduction (Table 2), there were no signifi-
cant changes in the carriage prevalence of PCV13 serotypes or
non-PCV13 serotypes in 5–8 week old infants, although the
expected trends of decreasing PCV13 serotype carriage and
increasing non-PCV13 serotype carriage were observed. In 12–
23 month old children, carriage prevalence of PCV13 serotypes
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was significantly lower in the post-PCV13 period, while there was
only a slight, non-significant increase in carriage prevalence of
non-PCV13 serotypes.
Fig. 1 shows the carriage prevalence for each of the PCV13 ser-
otypes and the 10 most common non-PCV13 serotypes in both age
groups, pre- and post-PCV13 introduction. For 5–8 week old
infants, 32/71 (45%) of pneumococci belonged to PCV13 serotypes
in the pre-PCV13 survey, compared with 27/90 (30%) post-PCV13
introduction (p = 0.049). The carriage prevalence of serotype 6A
was higher pre-PCV13 compared with the post-PCV13 survey
(11/495 [2.2%] vs 3/501 [0.6%], p = 0.030), whereas serotype 23A
prevalence was lower pre-PCV13 (0/495 [0.0%] vs post-PCV13
4/501 [0.8%], p = 0.046). The most common serotypes in the pre-
PCV13 period were 6A (n = 11), 15B/C, 6B, and NT2 (n = 6 each),
compared with NT2 (n = 15), 15B/C (n = 12), and 15A, 23F, 6B,
and 6C (n = 5 each) in the post-PCV13 period.
For 12–23 month old children, 176/323 (54.5%) of pneumococci
belonged to PCV13 serotypes in the pre-PCV13 survey, compared
Table 1
Characteristics of study participants in cross-sectional community pneumococcal carriage surveys, performed pre- and two years post-PCV13, in children in Lao PDR, by age group
and time period.
5–8 week old infants Pre-PCV13
N = 498a
Post-PCV13
N = 502
P value
Median age in weeks (IQR)b 6.7 (6.4–7.1) 6.7 (6.6–7.0) 0.475
Female sex, n (%) n = 501
242 (48.6) 248 (49.5) 0.774
Ethnicity, n (%) n = 501
Lao Loum 480 (96.4) 485 (96.8) 0.714
Minority groups 18 (3.6) 16 (3.6)
Residential location, n (%)
Urban 460 (92.4) 469 (93.4) 0.515
Rural 38 (7.6) 33 (6.6)
Two or more children <5 years in household, n (%) 195 (39.2) 215 (42.8) 0.238
Exposure to household cigarette smoke, n (%) n = 497
201 (40.4)
n = 500
166 (33.2) 0.018
Symptoms of URTIc, n (%) 97 (19.5) 71 (14.1) 0.024
Antibiotic use in previous fortnight, n (%) n = 502
24 (4.8) 5 (1.0) <0.001
Povertyd, n (%) 31 (6.2) 31 (6.2) 0.974
Born by vaginal delivery, n (%) 410 (82.3) 352 (70.1) <0.001
Breastfeeding at time of survey, n (%)
410 (82.3)
n = 501
435 (86.8) 0.049
Main source of cooking fuel, n (%)
Electricity 88 (17.7) 57 (11.4) 0.005
Charcoal 256 (51.4) 255 (50.8) 0.847
Wood 65 (13.0) 99 (19.7) 0.004
Gas 89 (17.9) 90 (17.9) 0.981
Kerosene 0 (0.0) 1 (0.2) 0.319
12–23 month old children Pre-PCV13 Post-PCV13 P value
N = 503 N = 507
Median age in months (IQR) 16.6 (14.7–20.0) 16.1 (14.6–20.3) 0.808
Female sex, n (%) 250 (49.7) 276 (54.4) 0.132
Ethnicity, n (%)
Lao Loum 474 (94.2) 489 (96.4) 0.095
Minority groups 23 (5.8) 18 (3.6)
Residential location, n (%)
Urban 250 (49.7) 290 (57.2) 0.017
Rural 253 (50.3) 217 (42.8)
Two or more children <5 years in household, n (%) 167 (33.2) 182 (35.9) 0.368
Exposure to household cigarette smoke, n (%) n = 502 n = 505 0.736
222 (44.2) 218 (43.2)
Symptoms of URTI, n (%) 373 (74.2) 264 (52.1) <0.001
Previously vaccinated with PCV13e, n (%) n = 502 <0.001
0 (0.0) 453 (90.2)
Antibiotic use in previous fortnight, n (%) n = 501 n = 506 <0.001
231 (46.1) 174 (34.4)
Povertyd, n (%) 34 (6.8) 19 (3.8) 0.032
Born by vaginal delivery, n (%) 426 (84.7) 405 (79.9) 0.045
Breastfeeding at time of survey, n (%) n = 502
410 (81.7) 398 (78.5) 0.207
Main source of cooking fuel, n (%) n = 501
Electricity 48 (9.6) 47 (9.3) 0.866
Charcoal 254 (50.7) 228 (45.0) 0.069
Wood 123 (24.5) 154 (30.4) 0.038
Gas 76 (15.2) 77 (15.2) 0.994
Kerosene 0 (0.0) 1 (0.2) 0.320
a Unless otherwise specified.
b IQR = Interquartile range.
c URTI = upper respiratory tract infection symptoms (includes any of the following: ear discharge, runny nose, and/or cough at time of survey).
d Rural poverty <196412.8 LKP/week; urban poverty <221391.1 LKP/week) [51].
e received at least 2 doses of PCV13 prior to survey.
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with 102/265 (38.5%) post-PCV13 introduction (p < 0.001). The car-
riage prevalence of PCV13 serotypes 6A and 6B, and non-PCV13
serotype 6C decreased following PCV13 introduction: for 6A,
32/501 (6.4%) pre-PCV13 compared with 15/504 (3.0%) post-
PCV13, p = 0.010; for 6B, 43/501 (8.6%) pre-PCV13 compared with
11/504 (2.2%) post-PCV13, p < 0.001; for 6C, 16/501 (3.2%)
Table 2
Carriage prevalence and prevalence ratios for pneumococcal carriage (overall, PCV13 serotypes, and non-PCV13 serotypes) for 5–8 week old infants (5–8 wk) and 12–23 month
old children (12–23 mo) pre- and two years post-PCV13 introduction.
Pre-PCV13 prevalence (%) (95% CI) Post-PCV13 prevalence (%) (95% CI) Unadjusted prevalence ratio (95% CI) Adjusted prevalence ratioa (95% CI)
All pneumococcib
5–8 wk 14.3 (11.3–17.6) 17.1 (13.9–20.7) 1.20 (0.90–1.60) 1.05 (0.77–1.43)
12–23 mo 55.8 (51.3–60.2) 45.6 (41.2–50.0) 0.82 (0.72–0.92) 0.89 (0.78–1.02)c
PCV13 serotypes
5–8 wk 6.5 (4.5–9.0) 5.2 (3.4–7.5) 0.80 (0.49–1.33) 0.74 (0.43–1.27)
12–23 mo 32.9 (28.8–37.2) 19.8 (16.4–23.6) 0.60 (0.49–0.75) 0.77 (0.61–0.96)c
Non-PCV13 serotypes
5–8 wk 7.7 (5.5–10.4) 12.2 (9.4–15.4) 1.59 (1.08–2.33) 1.29 (0.85–1.96)
12–23 mo 26.9 (23.1–31.1) 30.0 (26.0–34.2) 1.11 (0.91–1.35) 1.11 (0.89–1.38)
a The following variables were used to adjust the prevalence ratios for each age group: 5–8 week old (ethnicity, residential location, two or more children under five years
in the household, main source of cooking fuel, mode of delivery, poverty, and month of swab collection); 12–23 months old (ethnicity, residential location, two or more
children under five years in the household, URTI symptoms, mode of delivery, main source of cooking fuel, and month of swab collection).
b Overall carriage prevalence does not necessarily equal the sum of PCV13 serotype and non-PCV13 serotype prevalence. This is due to multiple serotype carriage and/or
exclusion of pneumococcal-positive samples for which serotype was not determined from analysis for PCV13 and non-PCV13 serotype carriage.
c Log-Binomial models did not converge, so Poisson models with robust 95% confidence intervals (CI) were used.
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Fig. 1. Carriage prevalence of PCV13 serotypes and the 10 most common non-PCV13 serotypes in 5–8 week old infants (A) and 12–23 month old children (B) before (pre-
PCV13) or after (post-PCV13) vaccine introduction. Solid bars indicate carriage that was detected as a single or major (dominant) serotype, open bars indicate carriage that
was detected as a minor (second or third) serotype. NT2 = non-encapsulated pneumococci containing nspA/pspK [28,52]. *p < 0.05, chi-squared test.
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pre-PCV13 compared with 6/504 (1.2%) post-PCV13, p = 0.030. In
contrast, non-PCV13 serotype 23A prevalence increased following
PCV introduction (from 3/501 [0.6%] to 15/504 [3.0%], p = 0.004).
The most common serotypes identified in this age group pre-
PCV13 were NT2 (n = 44), 6B (n = 43), 19F (n = 34) and 23F
(n = 34) compared with NT2 (n = 36), 15B/C (n = 30) and 19F
(n = 28) post-PCV13.
The majority of pneumococcal-positive samples contained a
single serotype (575/660, 87.1%); multiple serotype carriage was
relatively uncommon (85/660, 12.9%). Infants aged 5–8 weeks car-
ried a maximum of two serotypes, whereas children aged 12–
23 months carried up to three. The proportion of children with
multiple serotype carriage did not differ significantly pre- and
post-PCV13 introduction. For 5–8 week old infants, the prevalence
of multiple serotype carriage was 0.6% (95% CI: 0.1–1.7) pre-PCV13
and 1.0% (95% CI: 0.3–2.3) post-PCV13 introduction (p = 0.488). For
12–23 month old children, the prevalence of multiple serotype car-
riage was 8.2% (95% CI: 5.9–10.9) pre-PCV13, and 7.1% (95% CI:
5.0–9.7) post-PCV13 introduction (p = 0.535).
AMR genes were common, with 70.8% of samples containing at
least one of the 10 AMR genes assessed. PCV13 serotypes were
more likely to have at least one AMR gene detected (specifically
tetM, cat, mefA, and ermB), as well as being more likely to carry  3
AMR genes compared with non-PCV13 serotypes (Table 3). Non-
PCV13 serotypes were more likely to carry aphA3 than PCV13 ser-
otypes. When examining the pre- and post-PCV13 surveys, we
found that the proportion of samples from 5–8 week old infants
containing AMR genes did not change. However, in the 12–
23 month old children, the proportion of samples containing cat
decreased whilst sat4, ermB and ermC increased (Table 4).
In childrenwho carried pneumococci, densities for overall pneu-
mococci, PCV13 serotypes, and non-PCV13 serotypes were higher
in the post-PCV13 period compared with the pre-PCV13 period
for both age groups (Fig. 2). In 12–23 month old children, the den-
sity of pneumococci overall, PCV13 serotypes, and non-PCV13 ser-
otypes were higher in PCV13 vaccinated (2 or 3 doses) compared
with undervaccinated (0 or 1 dose) children (Table 5). Individual
serotype densities were examined for the eight most common ser-
otypes (PCV13 serotypes 19F, 23F, 6B, 6A, and 14, and non-PCV ser-
otypes NT2, 15B/C, and 11A). No differences in median density of
individual serotypes were observed between PCV13 vaccinated
and undervaccinated children (Supplementary Table).
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.10.
077.
4. Discussion
There is a paucity of data on the impact of PCVs from Asia, par-
ticularly from LMICs. In this study, we describe pneumococcal car-
riage in children aged 12–23 months and 5–8 week old infants,
who are too young to be vaccinated, before and two years after
PCV13 introduction in Lao PDR. In children aged 12–23 months,
there was a 23% reduction in PCV13 serotype carriage two years
after vaccine introduction. Although there was no significant
increase in carriage of non-vaccine serotypes, we observed a trend
Table 3
Antimicrobial resistance genes detected by microarray in nasopharyngeal samples from Laotian children aged 5–8 weeks and 12–23 months that contained a single
pneumococcal serotype with no other species identified. Detection rate of antimicrobial resistance genes shown for all pneumococci, PCV13 serotypes, and non-PCV13 serotypes.
Antimicrobial
resistance gene
Encodes
resistance to
Detected in all pneumococci
(N = 519) n (%)
Detected in PCV13 serotypes
(N = 236) n (%)
Detected in non-PCV13 serotypes
(N = 283) n (%)
P
valuea
tetM Tetracycline 305 (58.8) 199 (84.3) 106 (37.5) <0.001
tetK Tetracycline 47 (9.1) 16 (6.8) 31 (11.0) 0.099
tetO Tetracycline 1 (0.2) 0 (0.0) 1 (0.4) 0.361
tetL Tetracycline 1 (0.2) 1 (0.4) 0 (0.0) 0.273
cat Chloramphenicol 83 (16.0) 64 (27.1) 19 (6.7) <0.001
mefA Macrolides 127 (24.5) 81 (34.3) 46 (16.2) <0.001
aphA3 Kanamycin 20 (3.8) 4 (1.7) 16 (5.6) 0.020
sat4 Streptothricin 16 (3.1) 4 (1.7) 12 (4.2) 0.095
ermB Erythromycin 159 (30.6) 87 (36.8) 72 (25.4) 0.005
ermC Erythromycin 22 (4.2) 6 (2.5) 16 (5.6) 0.080
Any antimicrobial resistance gene 368 (70.9) 207 (87.7) 161 (56.9) <0.001
3 antimicrobial resistance genes 119 (22.8) 78 (33.0) 41 (14.5) <0.001
a PCV13 serotypes vs non-PCV13 serotypes.
Table 4
Antimicrobial resistance genes detected by microarray in nasopharyngeal samples from Laotian children containing a single pneumococcal serotype with no other species
identified, shown pre- and post-PCV13 introduction by age group.
5–8 week old infants 12–23 month old children
Antimicrobial resistance gene Pre-PCV13 (N = 62) n (%) Post-PCV13 (N = 72) n (%) P value Pre-PCV13 (N = 219) n (%) Post-PCV13 (N = 166) n
(%)
P value
tetM 37 (60) 34 (47) 0.150 131 (59.8) 103 (62.0) 0.657
tetK 22 (36) 16 (22) 0.089 4 (1.8) 5 (3.0) 0.446
cat 13 (21) 7 (10) 0.069 46 (21.0) 17 (10.2) 0.005
mefA 8 (13) 15 (21) 0.225 61 (27.8) 43 (25.9) 0.670
aphA3 7 (11) 5 (7) 0.380 2 (0.9) 6 (3.6) 0.066
sat4 7 (11) 3 (4) 0.118 1 (0.5) 5 (3.0) 0.045
ermB 15 (24) 22 (31) 0.411 55 (25.1) 67 (40.4) 0.001
ermC 7 (11) 8 (11) 0.974 1 (0.5) 6 (3.6) 0.022
Any antimicrobial resistance
gene
48 (77) 46 (64) 0.088 154 (70.3) 120 (72.3) 0.673
3 antimicrobial resistance
genes
19 (31) 21 (29) 0.852 42 (19.2) 37 (22.3) 0.454
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indicating that serotype replacement in carriage is beginning to
occur as we would expect [10,31–33].
In infants too young to be vaccinated, there was no significant
change in carriage of PCV13 serotypes or non-PCV13 serotypes.
However, the proportion of pneumococci that belonged to PCV13
serotypes was lower in the post-PCV13 period, providing some
early suggestive evidence for indirect effects of PCV13 in this age
group. Similar to the 12–23 month olds, an increasing trend in
non-PCV13 serotype carriage was observed. Further studies will
be needed to ascertain when indirect effects that result in a signif-
icant decrease in PCV13 serotype carriage prevalence will be
observed in this age group in Lao PDR.
This is one of the first studies to describe population based
nasopharyngeal carriage effects following PCV13 introduction,
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Fig. 2. Nasopharyngeal carriage density (log10 genome equivalents/ml) of all pneumococci, PCV13 serotypes, and non-PCV13 serotypes in 5–8 week old infants (A) and 12–
23 month old children (B). Boxes depict interquartile range (IQR) with a central line at the median, and whiskers extend 1.5 times IQR past the quartiles. Values outside
whiskers plotted as individual points. For both age groups, the median density of all pneumococci, PCV13 serotypes, and non-PCV13 serotypes was higher post-PCV13
compared with pre-PCV13 introduction. *p < 0.01, Mann-Whitney test.
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without prior PCV7 introduction. The only published data in this
context is from Greenland, where PCV13 was introduced using a
2 + 1 schedule with catch-up for children <23 months. In children
aged 0–6 years, a carriage study conducted in 2013 found an
adjusted odds ratio of 0.44 (p = 0.01) for PCV13 serotype carriage
compared with that of children sampled one year post-PCV13
introduction in 2011 [34]. There are five published studies examin-
ing population-based effects of the introduction of PCV10 (without
prior PCV7 introduction) on nasopharyngeal carriage. PCV10 was
introduced in Kenya in 2011 in a 3 + 0 schedule. Cross-sectional
carriage studies conducted in the Kilifi region, where a catch-up
campaign included children 12–59 months, found that two years
post-introduction there was a 64% decline in PCV10 serotype car-
riage in children <5 years and a 66% decline in people >5 years of
age [31]. In Brazil, a 91% reduction in PCV10 serotype carriage
was measured in 12–23 month old children approximately three
years following introduction using a 3 + 1 schedule with catch-up
vaccination for children <23 months of age [33]. PCV impact on
carriage was assessed in children attending day-care centres in Ice-
land following PCV10 introduction using a 2 + 1 schedule without
catch-up [32]. Approximately 2–4 years after PCV10 introduction,
there was a 94% and 56% reduction of PCV10 serotype carriage in
vaccinated children aged <4 years, and older children (3.5–
6.3 years) who were not eligible for vaccination, respectively. In
Fiji, three years after PCV10 was introduced using a 3 + 0 schedule
(with no catch-up) there was a 44% and 66% decline in PCV10 car-
riage for 5–8 week old unvaccinated infants and 12–23 month old
children, respectively [22]. Recently, Sigauque et al. reported a 41%
decline in PCV10 serotype carriage in HIV-uninfected children in
Mozambique two years after introduction using a 3 + 0 schedule
without catch-up [35].
The reductions in vaccine-type carriage that were observed in
Lao PDR were smaller than observed for Fiji, Iceland, Brazil and
Kenya. Differences in baseline demographics, vaccination schedule,
catch-up campaign used, PCV coverage and the number of years
post-PCV introduction are likely to contribute to differences in
the magnitude of reductions in vaccine-serotype carriage.
Of the >95 pneumococcal serotypes identified globally to date,
41 were represented in this study. We also identified several puta-
tive serotype variants (including the 11F-like variant described
previously [36]), which will be characterised further and used to
inform future carriage and disease surveillance. Non-
encapsulated pneumococci were common in our study population,
especially the NT2 lineage that is common in other settings [37–
39]. Carriage prevalence of PCV13 serotypes 6A and 6B was lower
post-PCV13 in 12–23 month old children, and 6A also decreased in
the 5–8 week old infants. Serotype 23A increased in both age
groups, and has been associated with serotype replacement in
invasive pneumococcal disease and otitis media following PCV13
introduction in other settings [40,41].
The effect of PCV on multiple serotype carriage is an open ques-
tion. Valente et al. [42,43] found evidence of a decline in multiple
serotype carriage with PCV introduction in Portugal. However, con-
sistent with Brugger et al. [44] and our recent study in Fiji [22], we
did not find evidence for an effect of PCV on the proportion of chil-
dren who carried more than one serotype in Lao PDR. Interestingly,
there was a significant decrease in the proportion of pneumococci
that were PCV13 serotypes (and a corresponding increase in the
proportion of pneumococci that were non-PCV13 serotypes) for
both age groups in Lao PDR, suggesting that changes in pneumo-
coccal serotype distribution may be a more sensitive measure of
vaccine impact in the early years post-PCV introduction, even in
the context of low multiple serotype carriage.
In Asia, antibiotic use is often unregulated and AMR is very
common [45,46], including for pneumococci. For example, nearly
60% of the 2184 pneumococci isolated from patients in 11 Asian
countries were resistant to at least three antibiotic classes [47].
Consistent with this, we found that over 70% of pneumococcal-
positive samples contained at least one AMR gene, and that over
40% of the 12–23 month old children had reported antibiotic use
in the preceding fortnight. Data on the presence of AMR genes
obtained by microarray can be used to provide an ecological snap-
shot of resistance genes in pneumococcal populations. PCV13 ser-
otypes were in general more likely to harbour resistance genes
compared with non-PCV13 serotypes, suggesting that Lao PDR
may be a setting where PCV introduction would be expected to
reduce the prevalence of AMR [13], although AMR genes were also
common in non-PCV13 serotypes. However, changes in the preva-
lence of AMR genes following PCV13 introduction was not neces-
sarily reflective of their distribution prior to vaccine introduction.
In particular, we observed an increase in ermB, which encodes
resistance to erythromycin, following PCV13 introduction in spite
of the fact that PCV13 serotypes were more likely to carry ermB
than non-PCV13 serotypes. This did not appear to be related to
an increase in a specific ermB harbouring clone. However, ermB
was commonly found in non-PCV13 serotypes 23A, 15A, and
11A, all of which became relatively more common in the post-
PCV13 survey. Other reasons that could contribute to changes in
AMR gene prevalence may include changes in antibiotic utilisation,
or possibly represent an increase in another colonising species car-
rying AMR genes that is present in the samples (and grows on
selective agar) but is not detected by microarray. Interestingly,
our recent study in Fiji also found that ermB prevalence increased
post-PCV introduction [22]. Analysis of AMR genes was limited to
those included on the microarray, and some antibiotics of clinical
importance with more complex mechanisms of resistance, such
Table 5
Median density and quantile regression analysis of overall pneumococci, PCV13 serotypes, and non-PCV13 serotypes in PCV13 vaccinated (2 or 3 doses) and undervaccinated
(0 or 1 dose) 12–23 month old children who were pneumococcal carriers.
Median density (IQR)a Unadjusted coefficient (95% CI)b P value Adjusted coefficient (95% CI)c P value
Overall pneumococci
Undervaccinated (304)d 5.60 (4.82–6.37) Reference Reference
PCV13 vaccinated (205) 6.00 (5.40–6.68) 0.43 (0.20–0.67) <0.001 0.50 (0.26–0.74) <0.001
PCV13 serotypes
Undervaccinated (176) 5.54 (4.84–6.28) Reference Reference
PCV13 vaccinated (89) 5.97 (5.30–6.54) 0.42 (0.09–0.75) 0.012 0.40 (0.07–0.73) 0.017
Non-PCV13 serotypes
Undervaccinated (149) 5.47 (4.65–6.35) Reference Reference
PCV13 vaccinated (135) 5.92 (5.23–6.69) 0.44 (0.12–0.77) 0.007 0.54 (0.20–0.87) 0.002
a Density reported in log10 genome equivalents/ml and interquartile range (IQR).
b Coefficient is the difference in medians as determined by quantile regression, reported with 95% confidence intervals (CI).
c Adjusted for ethnicity, URTI symptoms, and mode of delivery.
d Number of pneumococcal carriers shown in parentheses.
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as penicillin, were not assessed. Examining the clinical relevance
and impact of PCV on AMR requires phenotypic, and potentially
genotypic, testing.
There are few data on the impact of PCVs on pneumococcal den-
sity, and results to date have been contradictory. In a randomised-
controlled trial, American Indian children given PCV7 were less
densely colonised than those receiving the control meningococcal
vaccine [16]. Roca et al. reported a cluster-randomised trial in
The Gambia where vaccine serotype density was reduced in vacci-
nated and partially-vaccinated villages; however the density of
non-vaccine serotypes also declined, a finding difficult to explain
in the context of a PCV effect. Dagan et al. [17] also used semi-
quantitative methods and found that PCV13-vaccinated Israeli
children carried the six additional serotypes at the same density
as children vaccinated with PCV7. Recently, Olwagen et al. [48]
found that HIV uninfected 9 month old infants in South Africa
who were PCV7-vaccinated had higher carriage density compared
with unvaccinated infants from a separate study, however this
observation was consistent for both PCV7 and non-PCV7 serotypes,
and densities no longer differed when children were 16 months of
age.
In observational studies, Hanke et al. [49] found that PCV7 vac-
cination did not impact overall pneumococcal density (by qPCR) in
Peruvian children colonised with a PCV7 serotype, but density was
higher in vaccinated children colonised by a non-PCV7 serotype. In
our Fiji cross-sectional study, we found that both vaccine serotype
and non-vaccine serotype density was lower in vaccinated com-
pared with unvaccinated children aged 12–23 months, however
the effect may be temporal rather than vaccine-related [22]. In
Mozambique, density of serotypes 11A, 19A, and 19F were com-
pared pre- and post-PCV10 introduction and no differences were
observed [35]. In Lao PDR, we found that pneumococcal density
increased post-PCV introduction. Given that both PCV13 and
non-PCV13 density increased, we do not ascribe these changes to
PCV. We could not identify any field, clinical or laboratory changes
that could explain this observation, and so hypothesise that it may
be due to temporal variation and/or secular trends. Although high
pneumococcal density has been shown to be associated with respi-
ratory infections in children, we and others have shown that there
is considerable variability in pneumococcal carriage density, even
in healthy children [14,22,50]. Current evidence suggests that car-
riage density is not important in PCV impact studies, as no clear
links between PCV and pneumococcal density have been demon-
strated. However, further research to elucidate the respective roles
of pneumococcal carriage, density in the nasopharynx, and sero-
type in the development of pneumococcal disease is warranted.
Key strengths of this study are that we used sensitive molecular
methods [18,21] to measure prevalence and density of pneumo-
coccal carriage, in a lower-middle income setting where vaccine
impact data are sparse. Carriage is a practical and biologically rel-
evant end-point, but does not measure the impact of PCV on dis-
ease. Carriage surveys are able to be implemented quickly, and in
settings without prior surveillance data. This was valuable in Lao
PDR where we were able to roll out carriage surveys alongside vac-
cine introduction to provide baseline data. For programmatic rea-
sons, the baseline survey was conducted in the four months
following vaccine introduction. However, there were no PCV vacci-
nees in the first survey, and this is a period of time unlikely to
result in any herd effects that could confound baseline results. Rel-
atively few participants belonged to minority ethnic groups, and in
the 5–8 week age group, over 90% of participants were urban. This
may limit generalisability of our findings to the whole Lao PDR
population. Nevertheless, our study provides important supportive
evidence of the effects of PCV13 on carriage in Lao PDR; declines in
PCV13 serotype carriage are likely to translate into declines in dis-
ease caused by PCV13 serotypes. We expect that serotype replace-
ment in carriage in Lao PDR will become more prominent over
time. Ongoing surveillance is required.
This study provides evidence of PCV impact following introduc-
tion in a lower-middle income country in Asia. This is important, as
there are very little available data from this region despite the high
burden of disease. Our results are consistent with the large body of
evidence from high-income settings, and growing evidence from
low- and middle-income settings, that PCV use results in declines
in vaccine serotype carriage in both vaccinated and unvaccinated
individuals. Our data, together with other on-going studies (includ-
ing those funded by Gavi, the Vaccine Alliance), will provide a
stronger evidence base for PCV introduction and maintenance in
the region.
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